ଅକ୍ସଫୋର୍ଡ-ଆଷ୍ଟ୍ରାଜେନେକା ଜୋଭିଡ ୧୯ ଟିକା
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Trade names | Vaxzevria,[୧] Covishield[୨] |
Other names | Verity, AZD1222,[୩] ChAdOx1 nCoV-19,[୪] ChAdOx1-S,[୫] COVID-19 Vaccine AstraZeneca,[୬][୭] AZD2816[୮] |
License data |
|
Pregnancy category |
|
Routes of administration |
Intramuscular |
Drug class | COVID-19 vaccine[୧] |
Legal status | |
Legal status |
|
ଅକ୍ସଫୋର୍ଡ-ଆଷ୍ଟ୍ରାଜେନେକା ଜୋଭିଡ ୧୯ ଟିକା, ବିକ୍ରୟ ନାମ କୋଭିଶିଲ୍ଡ ଏବଂ ଭାକ୍ସେଭ୍ରିଆ, ହେଉଛି ଏକ ଜୋଭିଡ ୧୯ ଟିକା ।[୧] [୧୯] ଜୋଭିଡ ୧୯ ରୋକିବା ପାଇଁ ଏହା ୧୭7 ବର୍ଷରୁ ଅଧିକ ଲୋକଙ୍କଠାରେ ବ୍ୟବହୃତ ହୁଏ|। [୧] ପ୍ରାରମ୍ଭିକ ପରୀକ୍ଷଣରୁ ଜଣାପଡିଛି ଯେ ଏହା ଲକ୍ଷଣାତ୍ମକ ଜୋଭିଡ ୧୯ ଟିକାର ବିପଦକୁ ୬୦-୭୪% ହ୍ରାସ କରିଥାଏ | [୧] ଯୁବକମାନଙ୍କ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ସମ୍ଭାବନା ହେତୁ କେତେକ ଦେଶ ବୟସ୍କ ବ୍ୟକ୍ତିଙ୍କ ପାଇଁ ଏହାର ବ୍ୟବହାରକୁ ସୀମିତ କରିଛନ୍ତି ।[୨୦] ମାଂସପରଶୀରେ ଇଞ୍ଜେକସନ ଆକାରରେ ୪ରୁ ୧୨ ସପ୍ତାହ ବ୍ୟବଧାନରେ ଏହି ଟିକା ଦିଆଯାଏ [୧]
ଅଧିକାଂଶ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ସାମାନ୍ୟରୁ ମଧ୍ୟମ ଧରଣରୁ ହୁଏ ଏବଂ କିଛି ଦିନ ମଧ୍ୟରେ ଉପଶମ ହୋଇଯାଏ । [୧] ଉକ୍ତ ପ୍ରତିକ୍ରିୟା ମଧ୍ୟରେ ଇଞ୍ଜେକ୍ସନ୍ ନେବା ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା, ମୁଣ୍ଡବିନ୍ଧା, ଥକ୍କା, ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା ଏବଂ ବାନ୍ତି ହୋଇପାରେ ।[୧] ବିରଳ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କମ୍ ପ୍ଲାଟେଲେଟ୍, ଫେସିଆଲ୍ ପାଲସି, ରକ୍ତ ଜମାଟ ବାନ୍ଧିବା, ଗୁଲେନ୍-ବାରେ ସିଣ୍ଡ୍ରୋମ, ଆନାଫାଇଲକ୍ସିସ୍ ଏବଂ କ୍ୟାପିଲାରୀ ଲିକ୍ ସିଣ୍ଡ୍ରୋମ ହୋଇପାରେ ।[୧] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ନିର୍ଦ୍ଦିଷ୍ଟ କ୍ଷତିର କୌଣସି ପ୍ରମାଣ ନାହିଁ, ଯଦିଓ ଏହିପରି ବ୍ୟବହାରର ଭଲ ଭାବରେ ଅଧ୍ୟୟନ କରାଯାଇ ନାହିଁ ।[୨୧] ଏହା ଏକ ଭାଇରାଲ୍ ଭେକ୍ଟର ଟିକା, ଅର୍ଥାତ୍ ଏହା ଅନ୍ୟ ଏକ ଭୂତାଣୂ ( ଆଡେନୋଭାଇରସ୍ )ଦ୍ୱାରା ଗଠିତ ଜିନକୁ ଏସଏଆଅରଏସ-କୋଭ-୨ ଭୂତାଣୁର ସ୍ପାଇକ ପ୍ରୋଟିନ୍ ତିଆରି ପାଇଁ ପରିବର୍ତ୍ତିତ ହୋଇଛି | [୧]
୩୦ ଡିସେମ୍ବର ୨୦୨୦ରେ ଏହି ଟିକାକୁ ବ୍ରିଟେନରେ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦନ କରାଯାଇଥିଲା । [୨୨] ଏହା ପରବର୍ତ୍ତୀ ସମୟରେ ୨୦୨୨ ସୁଦ୍ଧା ଅତି କମରେ ୧୮୨ଟି ଦେଶରେ କିଛି ସ୍ତରରେ ବ୍ୟବହାର ପାଇଁ ଅନୁମତି ପ୍ରାପ୍ତ ହୋଇଛନ୍ତି ।[୨୩] ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନଦ୍ୱାରା ଜରୁରୀକାଳୀନ ବ୍ୟବହାର ତାଲିକା ପାଇଁ ଏହାକୁ ଅନୁମୋଦିତ ହୋଇଛି | [୨୪] ବ୍ରିଟେନରେ ଅକ୍ସଫୋର୍ଡ ୟୁନିଭରସିଟି ଏବଂ ବ୍ରିଟିଶ-ସ୍ୱିଡେନ କମ୍ପାନୀ ଆଷ୍ଟ୍ରାଜେନେକାଦ୍ୱାରା ଏହା ବିକଶିତ ହୋଇଥିଲା ।[୨୫] [୨୬] ଜାନୁଆରୀ ୨୦୨୨ ସୁଦ୍ଧା ସାରା ବିଶ୍ୱରେ ୨.୫ ବିଲିୟନରୁ ଅଧିକ ଡୋଜ ଦିଆଯାଇଛି । [୨୫] ଏହାର ଏକ ମାତ୍ରା ପାଇଁ ପ୍ରାୟ ୨ରୁ ୫ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ । [୨୭] ଏହି ଟିକା ରେଫ୍ରିଜରେଟର ତାପମାତ୍ରାରେ ୬ ମାସ ପର୍ଯ୍ୟନ୍ତ ସ୍ଥିର ରହିପାରେ । [୨୮]
- ↑ ୧.୦୦ ୧.୦୧ ୧.୦୨ ୧.୦୩ ୧.୦୪ ୧.୦୫ ୧.୦୬ ୧.୦୭ ୧.୦୮ ୧.୦୯ ୧.୧୦ "Vaxzevria (previously COVID-19 Vaccine AstraZeneca) EPAR". European Medicines Agency (EMA). Archived from the original on 21 April 2021. Retrieved 27 March 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Already produced 40–50 million dosages of Covishield vaccine, says Serum Institute". The Hindu. 28 December 2020. Archived from the original on 20 April 2021. Retrieved 30 December 2020.
- ↑ "AstraZeneca COVID-19 Vaccine (AZD1222)" (PDF). AstraZeneca. 27 January 2021. Archived (PDF) from the original on 27 January 2021. Retrieved 7 March 2021.
- ↑ "AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine". AstraZeneca (Press release). 30 April 2020. Archived from the original on 16 November 2020. Retrieved 13 January 2021.
- ↑ ୫.୦ ୫.୧ ୫.୨ "COVID-19 Vaccine AstraZeneca PI". Therapeutic Goods Administration (TGA). Archived from the original on 2021-07-31. Retrieved 2022-01-24.
- ↑ ୬.୦ ୬.୧ "COVID-19 Vaccine AstraZeneca". Therapeutic Goods Administration (TGA). 16 February 2021. Archived from the original on 18 March 2021. Retrieved 16 February 2021.
- ↑ ୭.୦ ୭.୧ "Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Archived from the original on 9 March 2021. Retrieved 4 January 2021.
- ↑ "First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated". Astrazeneca. 27 June 2021. Archived from the original on 27 June 2021. Retrieved 24 July 2021.
- ↑ "Summary for ARTG Entry: 349072 COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection multidose vial"[permanent dead link].
{{</nowiki>cite web}}</nowiki>
: CS1 maint: url-status (link) - ↑ "COVID-19 vaccine: AstraZeneca ChAdOx1-S". Therapeutic Goods Administration (TGA). 27 August 2021. Archived from the original on 23 October 2021. Retrieved 22 October 2021.
- ↑ "Brazil grants full approval to Oxford vaccine, orders Sputnik". Brasilia: France 24. Agence France-Presse. 12 March 2021. Archived from the original on 16 March 2021. Retrieved 13 March 2021.
- ↑ "Anvisa aprova registro da vacina da Fiocruz/AstraZeneca e de medicamento contra o coronavírus" [Anvisa approves registration of Fiocruz/AstraZeneca vaccine and drug against the coronavirus] (in Portuguese). Federal government of Brazil. Brazilian Health Regulatory Agency. 20 November 2021. Archived from the original on 20 November 2021. Retrieved 20 November 2021.
- ↑ "Regulatory Decision Summary - Vaxzevria". Health Canada. Archived from the original on 26 November 2021. Retrieved 26 November 2021.
- ↑ "AstraZeneca COVID-19 Vaccine monograph" (PDF). AstraZeneca. 26 February 2021. Archived (PDF) from the original on 30 March 2021. Retrieved 5 March 2021.
- ↑ "Conditions of Authorisation for COVID-19 Vaccine AstraZeneca". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Archived from the original on 18 February 2021. Retrieved 4 January 2021.
- ↑ "European Commission authorises third safe and effective vaccine against COVID-19". European Commission (Press release). Archived from the original on 10 February 2021. Retrieved 29 January 2021.
- ↑ "아스트라제네카社 코로나19 백신 품목허가" [AstraZeneca's Corona 19 vaccine product license]. 식품의약품안전처 (in Korean). 식품의약품안전처. 10 February 2021. Archived from the original on 10 February 2021. Retrieved 10 February 2021.
- ↑ "Covishield and Covaxin: What we know about India's Covid-19 vaccines". BBC News. 4 March 2021. Archived from the original on 7 March 2021. Retrieved 8 March 2021.
- ↑ "Spain, Belgium and Italy restrict AstraZeneca Covid vaccine to older people". The Guardian. 8 April 2021. Archived from the original on 9 April 2021. Retrieved 11 April 2021.
- ↑ Administration, Australian Government Department of Health Therapeutic Goods (16 February 2021). "COVID-19 Vaccine AstraZeneca". Therapeutic Goods Administration (TGA) (in ଇଂରାଜୀ). Archived from the original on 18 March 2021. Retrieved 30 January 2022.
- ↑ "Second COVID-19 vaccine authorised by medicines regulator" (Press release). 30 December 2020. Archived from the original on 15 March 2021. Retrieved 6 March 2021.
- ↑ Holder, Josh (29 January 2021). "Tracking Coronavirus Vaccinations Around the World". The New York Times. Archived from the original on 22 December 2021. Retrieved 28 January 2022.
- ↑ "Coronavirus disease (COVID-19): Vaccines". World Health Organization (WHO). Archived from the original on 18 December 2020. Retrieved 6 March 2021.
- ↑ ୨୫.୦ ୨୫.୧ "One year anniversary of UK deploying Oxford-AstraZeneca vaccine". gov.uk. Archived from the original on 4 January 2022. Retrieved 4 January 2022.
- ↑ Corum, Jonathan; Zimmer, Carl (17 December 2020). "How the Oxford-AstraZeneca Vaccine Works". The New York Times. Archived from the original on 5 January 2022. Retrieved 30 January 2022.
- ↑ Dyer, Owen (29 January 2021). "Covid-19: Countries are learning what others paid for vaccines". BMJ: n281. doi:10.1136/bmj.n281.
{{cite journal}}
:|access-date=
requires|url=
(help) - ↑ "Management of COVID-19 vaccine AstraZeneca (ChAdOx1-S) from refrigerator to administration - Vaccination". www.health.nsw.gov.au. Archived from the original on 18 November 2021. Retrieved 30 January 2022.